MedTrace Logo

Study of [11C]CPPC as a Clinical PET Radioligand Biomarker of Microglial Activation in ALS

NCT05602142 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-04-13

No results posted yet for this study

Summary

1. Establish the safety and tolerability of the 5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide (\[11C\]CPPC) PET radioligand in ALS patients and controls
2. Examine whether \[11C\]CPPC PET uptake is elevated in brains of ALS patients and whether there is a correlation with clinical phenotype.
3. Correlate \[11C\]CPPC PET imaging with other ALS outcome measures and biofluid biomarkers
4. Examine longitudinal changes in \[11C\]CPPC PET imaging during disease course.

Conditions

Interventions

DRUG

[11C]CPPC PET ligand

Radioactive PET ligand to determine microglia expression of colony stimulating factor 1 receptor (CSF1R).

Sponsors & Collaborators

Principal Investigators

  • Nicholas Maragakis, MD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-01-31
Completion
2027-07-31
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05602142 on ClinicalTrials.gov